Table 3.
HD IL-2 Plus gp100 209-2 M Peptide Vaccine Trial
| Response by WHO Criteria |
|||||
|---|---|---|---|---|---|
| Cohort | No. of Patients Assessed | No. of CR | No. of PR | RR (%) | 95% CI* (%) |
| Overall | 121 | 11 | 9 | 16.5 | 10 to 26 |
| Trial 1 | 42 | 6 | 4 | 23.8 | 12 to 40 |
| Trial 2 | 40 | 4 | 1 | 12.5 | 4 to 27 |
| Trial 3 | 39 | 1 | 4 | 12.8 | 4 to 27 |
| HD IL-2 database | 270 | 17 | 26 | 15.9 | 12 to 21 |
| NCI-surgery branch trial | 31 | 13† | 41.9 | 26 to 59 | |
Abbreviations: HD IL-2, high-dose interleukin-2; CR, complete response; PR, partial response; RR, response rate; NCI, National Cancer Institute.
*
CIs based on the binomial distribution.
†
CR + PR.